Clorox (CLX, Financial) shares experienced a noteworthy development as UBS analyst Peter Grom announced a revision in the price target and maintained the existing rating. The recent update was disclosed on July 17, 2025.
UBS has decided to lower the price target for Clorox (CLX, Financial) from a previous level of 150.00 USD to a new target of 134.00 USD. This adjustment represents a decline of 10.67% from the prior price target, signaling a more cautious outlook on the stock's future performance.
Despite the decrease in the price target, UBS continues to maintain a "Neutral" rating on Clorox (CLX, Financial). This indicates that the analysts foresee a balanced risk-reward scenario for investors at the current valuation levels.
Investors and market participants are advised to take note of this updated price target and consider it in their investment decision-making process regarding Clorox (CLX, Financial).
Wall Street Analysts Forecast
Based on the one-year price targets offered by 17 analysts, the average target price for Clorox Co (CLX, Financial) is $141.54 with a high estimate of $189.00 and a low estimate of $119.00. The average target implies an upside of 10.45% from the current price of $128.15. More detailed estimate data can be found on the Clorox Co (CLX) Forecast page.
Based on the consensus recommendation from 21 brokerage firms, Clorox Co's (CLX, Financial) average brokerage recommendation is currently 3.0, indicating "Hold" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Clorox Co (CLX, Financial) in one year is $144.17, suggesting a upside of 12.5% from the current price of $128.15. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Clorox Co (CLX) Summary page.
